Unacylated Ghrelin is associated with the isolated low HDL-cholesterol obese phenotype independently of insulin resistance and CRP level

Nutrition & Metabolism

René Valéro¹  Bernard Vialettes²  Henri Portugal⁷  Alain Nicolay⁷  Jean Gaudart⁴  Catherine Mattei²  Rachel Grangeot²  Noémie Dubois²  Audrey Bégu-Le Corroller²  Bruno Berthet⁶  Anne Marie Lorec⁷  Sophie Béliard⁵  Marie Maraninchi³  Juan-Patricio Nogueira³ 

[1] Service de Nutrition, Maladies métaboliques et Endocrinologie, Hôpital La Timone, 264 Rue Saint Pierre, 13005 Marseille, France;Aix-Marseille Univ, APHM, La Timone Hospital, Department of Nutrition, Metabolic diseases, Endocrinology, 13005 Marseille, France;Aix-Marseille Univ, UMR 1260, 13005 Marseille, France;Aix-Marseille Univ, EA 3283, Biostatistics Research Unit, Laboratory of Education and Research in Medical Information Processing (LERTIM), 13005 Marseille, France;UMR INSERM 939, La Pitié Hospital, Paris, France;Aix-Marseille Univ, APHM, La Timone Hospital, Department of Digestive Surgery, 13005 Marseille, France;Aix-Marseille Univ, APHM, Sainte Marguerite Hospital, Department of Biochemistry, 13005 Marseille, France

关键词: Obesity;    Lipids;    Insulin resistance;    Inflammation;    HDL-cholesterol;    Ghrelin;    Cardiovascular risk;    Apolipoprotein;    Adiponectin;   

Others  :  820020
DOI  :  10.1186/1743-7075-9-17

 received in 2011-10-21, accepted in 2012-03-13,  发布年份 2012

【 摘 要 】

Background

Low plasma high-density lipoprotein-cholesterol (HDL-c) level is commonly present in obesity and represents an independent cardiovascular risk factor. However, obese patients are a very heterogeneous population and the factors and mechanisms that contribute to low HDL-c remain unclear. The aim of this study was to investigate the association between plasma HDL-c levels and plasma hormonal profiles (insulin, adiponectin, resistin, leptin and ghrelin) in subsets of class II and III obese patients.

Methods

Fasting plasma levels of glucose, total cholesterol, LDL-c, HDL-c, triglycerides, free fatty acids, apoproteins A-I, B-100, B-48, C-II, C-III, insulin, hs-CRP, adipocytokines (adiponectin, resistin, leptin), unacylated ghrelin, body composition (DXA) and resting energy expenditure were measured in three subsets of obese patients: 17 metabolically abnormal obese (MAO) with metabolic syndrome and the typical metabolic dyslipidaemia, 21 metabolically healthy obese (MHO) without metabolic syndrome and with a normal lipid profile, and 21 isolated low HDL-c obese patients (LHO) without metabolic syndrome, compared to 21 healthy lean control subjects.

Results

Insulin resistance (HOMA-IR) increased gradually from MHO to LHO and from LHO to MAO patients (p < 0.05 between MHO and MAO and between LHO and MAO). In multiple regression analysis, serum unacylated ghrelin levels were only positively and independently associated with HDL-c levels in the LHO group (p = 0.032).

Conclusions

These results suggest that, in class II and III obese patients with an isolated low HDL-c phenotype, unacylated ghrelin is positively associated with HDL-c level independently of insulin resistance and CRP levels, and may contribute to the highly prevalent low HDL-c level seen in obesity.

【 授权许可】

   
2012 Nogueira et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365:1415-1428.
• [2]Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R, Lewington S, MacMahon S, Aromaa A, Baigent C, Carstensen J, Chen Z, Duffy S, Kromhout D, Neaton J, Rodgers A, Tominaga S, Törnberg S, Tunstall-Pedoe H, Chambless L, De Backer G, De Bacquer D, Kornitzer M, Whincup P, Wannamethee SG, Wald N, Morris R, et al.: Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009, 373:1083-1096.
• [3]Adiels M, Olofsson SO, Taskinen MR, Boren J: Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.
• [4]Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
• [5]Karelis AD: Metabolically healthy but obese individuals. Lancet 2008, 372:1281-1283.
• [6]Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR: The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008, 168:1617-1624.
• [7]McLaughlin T, Lamendola C, Liu A, Abbasi F: Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab 2011, 96:1756-1760.
• [8]Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP: Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009, 53:577-584.
• [9]Zou C, Shao J: Role of adipocytokines in obesity-associated insulin resistance. J Nutr Biochem 2008, 19:277-286.
• [10]Peterson RM, Beeson L, Shulz E, Firek A, De Leon M, Balcazar H, Tonstad S, Cordero-Macintyre ZR: Impacting obesity and glycemic control using a culturally-sensitive diabetes education program in Hispanic patients with type 2 diabetes. Int J Body Compos Res 2010, 8:85-94.
• [11]Watts GF, Gan SK: Nutrition and metabolism: non-alcoholic fatty liver disease - pathogenesis, cardiovascular risk and therapy. Curr Opin Lipidol 2008, 19:92-94.
• [12]Boes E, Coassin S, Kollerits B, Heid IM, Kronenberg F: Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review. Exp Gerontol 2009, 44:136-160.
• [13]Barazzoni R, Zanetti M, Ferreira C, Vinci P, Pirulli A, Mucci M, Dore F, Fonda M, Ciocchi B, Cattin L, Guarnieri G: Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J Clin Endocrinol Metab 2007, 92:3935-3940.
• [14]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr: Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
• [15]Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF: Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol 2006, 26:1357-1363.
• [16]Rashid S, Watanabe T, Sakaue T, Lewis GF: Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003, 36:421-429.
• [17]Lopez-Miranda J, Williams C, Lairon D: Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. Br J Nutr 2007, 98:458-473.
• [18]Beliard S, Nogueira JP, Maraninchi M, Lairon D, Nicolay A, Giral P, Portugal H, Vialettes B, Valero R: Parallel increase of plasma apoproteins C-II and C-III in Type 2 diabetic patients. Diabet Med 2009, 26:736-739.
• [19]Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH: Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005, 54:795-802.
• [20]Martin LJ, Woo JG, Daniels SR, Goodman E, Dolan LM: The relationships of adiponectin with insulin and lipids are strengthened with increasing adiposity. J Clin Endocrinol Metab 2005, 90:4255-4259.
• [21]Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB: Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004, 27:1680-1687.
• [22]Chan DC, Barrett PH, Ooi EM, Ji J, Chan DT, Watts GF: Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J Clin Endocrinol Metab 2009, 94:989-997.
• [23]Verges B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, Gambert P: Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol 2006, 26:1364-1369.
• [24]Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA: Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care 2005, 28:2181-2186.
• [25]Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333.
• [26]Tan CY, Vidal-Puig A: Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Biochem Soc Trans 2008, 36:935-940.
• [27]Magkos F, Fabbrini E, McCrea J, Patterson BW, Eagon JC, Klein S: Decrease in hepatic very-low-density lipoprotein-triglyceride secretion after weight loss is inversely associated with changes in circulating leptin. Diabetes Obes Metab 2010, 12:584-590.
• [28]Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374.
• [29]Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O: Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003, 52:2546-2553.
• [30]Beaumont NJ, Skinner VO, Tan TM, Ramesh BS, Byrne DJ, MacColl GS, Keen JN, Bouloux PM, Mikhailidis DP, Bruckdorfer KR, Vanderpump MP, Srai KS: Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem 2003, 278:8877-8880.
• [31]Le NA, Ginsberg HN: Heterogeneity of apolipoprotein A-I turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. Metabolism 1988, 37:614-617.
• [32]Brinton EA, Eisenberg S, Breslow JL: Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest 1991, 87:536-544.
• [33]Gylling H, Vega GL, Grundy SM: Physiologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids. J Lipid Res 1992, 33:1527-1539.
• [34]Ji J, Watts GF, Johnson AG, Chan DC, Ooi EM, Rye KA, Serone AP, Barrett PH: High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J Clin Endocrinol Metab 2006, 91:973-979.
• [35]Choi HJ, Cho YM, Moon MK, Choi HH, Shin HD, Jang HC, Kim SY, Lee HK, Park KS: Polymorphisms in the ghrelin gene are associated with serum high-density lipoprotein cholesterol level and not with type 2 diabetes mellitus in Koreans. J Clin Endocrinol Metab 2006, 91:4657-4663.
• [36]Martin GR, Loredo JC, Sun G: Lack of association of ghrelin precursor gene variants and percentage body fat or serum lipid profiles. Obesity (Silver Spring) 2008, 16:908-912.